
The company said responses persisted through Week 52 in a Phase III study and plans further regulatory submissions for chronic inducible urticaria.
Novartis said Rhapsido showed sustained efficacy through Week 52 in a Phase III study of chronic inducible urticaria, spanning three subtypes. The company plans additional regulatory submissions based on the results.
In the RemIND study, complete or partial response rates at Week 52 ranged from 46.8% to 83.3% among patients initially assigned Rhapsido. Patients who switched from placebo to Rhapsido at Week 24 had rates ranging from 47.7% to 88.9%, depending on subtype.
Novartis said the drug was well tolerated through Week 52, with a safety profile consistent with previous studies and its established experience in chronic spontaneous urticaria. The results will be presented at the American College of Allergy, Asthma & Immunology annual meeting.
As of Thursday, Nov. 12 at 16:30 UTC, Novartis shares traded at CHF 134.22, up 1.11% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.